Email :
Contact : (321) 445-1969

Role of immunotherapy for H. pylori in gastric cancer.


Gastric cancer is a well-known challenging health problem in the world, which has been deemed to be associated with Helicobacter pylori (H. pylori). H. pylori avoid the endogenous immune reactions. An effective production of antibody against H. pylori is critical. There are known conventional as well as experimental treatments associated with H. pylori. Immune therapy may be considered a cornerstone of treatments. Immunization against H. pylori may be deemed as safe and effective among many populations. H. pylori colonize the gastric mucosa of more than half of the world. Most of the aggravation associated with its infection is deemed as innocuous and/or clinically asymptomatic to treat. However, it may lead to perpetual gastritis, peptic ulcer, gastric mucosa-related lymphoid tissue lymphoma, and gastric cancer. The actual role of immune system for gastric cancer is discussed in this article. Lately, T regulatory cells (T reg) have been inferred to be a vital part in H. pylori-related advancement. Additionally, T reg-actuated tolerance has been suggested as a plausible tool that presumes less serious infection. A number of clinical trials have shown the mechanism of immune response against H. pylori in line with the induction in gastric cancer.

Key words: Helicobacter pylori, vaccines, T regulatory cells, gastric cancer, lymphoid tissue, lymphoma, GIT.

Download Pdf